Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTICAL: Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma
NCT07356973Phase 2Recruiting
- Sponsor
- CRISM Therapeutics
- Start
- Aug 2026
- Primary completion
- May 2029
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan-ChemoSeed in glioblastoma (GBM), sponsored by CRISM Therapeutics. Started Aug 2026; status: recruiting.
02
Drugs
irinotecan-ChemoSeed
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07356973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07356973.